First Patients Treated in COVID-19 Stem Cell Clinical Trial
In 2020, Personalized Stem Cells developed and secured FDA approval for a COVID-19 stem cell clinical trial. In October of last year, we announced that we out-licensed our allogeneic stem cell program, including the COVID-19 therapy, to Sorrento Therapeutics....
A Long and Winding Road: Meet PSC President and COO Mike Dale
Mike Dale is President and Chief Operating Officer of Personalized Stem Cells, Inc. (PSC), and co-founder of our parent company, VetStem Biopharma. Mike’s journey is not the typical biotech career path. In the 1970’s Mike had no scientific or biotech aspirations or...
Knee Osteoarthritis Clinical Trial Update: Data Collection Milestone
2020 was a whirlwind of a year for most of us. Individuals, families, and businesses all over the world were affected by the global pandemic. Nobody expected the year’s crazy turn of events, and most of us found ourselves in uncharted territory when it came to...
Stem Cell Therapy for Traumatic Brain Injury
Stem cell therapy may be an effective treatment option for traumatic brain injury.
Personalized Stem Cells’ Parent Company Celebrates 15 Years as Biocom Member
Our parent company, VetStem Biopharma, recently reached their 15 year anniversary as a member of Biocom, a life science association.
Meet Dr. Robert Harman, Co-Founder and CEO of Personalized Stem Cells
Co-Founder and CEO of Personalized Stem Cells Inc., Dr. Robert Harman, has dedicated the majority of his career to developing stem cell therapy for humans and animals.
Stem Cell Therapy for Pain Management
Recent literature supports the notion that stem cells have the ability to directly modulate pain.
One Medicine: Animals Helping People
Nearly two decades’ worth of experience in the veterinary field led to the formation of Personalized Stem Cells, a human adipose-derived stem cell company.
Personalized Stem Cells Out-Licenses Allogeneic Stem Cell Program Including COVID-19 Therapy
Personalized Stem Cells announces licensing agreement for its allogeneic stem cell program including COVID-19 therapy.
Faith in Regenerative Medicine: Securing Funding During Uncertain Times
Personalized Stem Cells secured $2.5 million during a Series A round of financing in spite of the current economic crisis.